Share General Information
Dasatinib monohydrate is a kinase inhibitor indicated for the treatment of ‘ newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase ‘ adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib ‘ adults with Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy.
About the API
-
Japan DMF
-
Korea DMF
-
US DMF
Updates About Dasatinib Monohydrate
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
